Trial Profile
Prospective observational study to investigate the risk of hematoma formation in total hip arthroplasty patients receiving rivaroxaban and peripheral nerve block concurrently
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Adverse reactions
- 10 Dec 2015 New trial record